Affection Deprivation and Weathering: An Exploratory Study of Black and African Americans’ Well-Being during COVID-19

This study investigates factors related to the well-being of African Americans during the COVID-19 pandemic, specifically, reports of discrimination, perceived stress, and affection deprivation through the lenses of Affection Exchange Theory and the Weathering Framework. Sixty-six individuals participated in a cross-sectional survey study through an online Qualtrics questionnaire. We predicted that Black and African American participants would report experiencing more discrimination during the pandemic than other people of color (POC) due to several overlapping pathways of racism (e.g., stereotype effect, internalized racism, and systemic racism) affecting Black individuals more than others. We also predicted affection deprivation for Black and African American participants would be directly related to their perceived stress. Results from an independent samples t-test indicated no significant difference of discrimination between Black and non-Black participants. However, in post hoc analysis, there was a significant difference of discrimination between Black and White participants, illustrating the greater strain on Black individuals during the pandemic when compared to their White counterparts. Finally, correlational analysis revealed a significant positive association between affection deprivation and perceived stress for Black participants. We believe this relationship reflects an important health problem Black Americans are facing during the COVID-19 pandemic, in which isolation through COVID-19 protective measures (e.g., quarantine) are exacerbating the burden of stress they already bear

Preliminary Results on HAT-P-4, TrES-3, XO-2, and GJ 436 from the NASA EPOXI Mission

EPOXI (EPOCh + DIXI) is a NASA Discovery Program Mission of Opportunity using the Deep Impact flyby spacecraft. The EPOCh (Extrasolar Planet Observation and Characterization) Science Investigation will gather photometric time series of known transiting exoplanet systems from January through August 2008. Here we describe the steps in the photometric extraction of the time series and present preliminary results of the first four EPOCh targets.Comment: 4 pages, 2 figures. To appear in the Proceedings of the 253rd IAU Symposium: "Transiting Planets", May 2008, Cambridge, M

March 1965

Turf and Lawn Grass Association Better turf through research and Educatio

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years